Vol 53 No 08

"Pediatric-type cancer diagnoses in adults are rare, and there are important differences in caring for children with genitourinary malignancies compared with adults," write the authors.

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

"As always, we encourage you to communicate among all team members and pay attention to your documentation," write Jonathan Rubenstein, MD, and Mark Painter.

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

According to the authors, these data support Rezūm as an alternative first-line treatment option for patients at risk of BPH progression.

Mitomycin intravesical solution was granted FDA approval in June 2025 for recurrent LG-IR-NMIBC.

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.

“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.

In healthy aging men without developing diabetes mellitus, modest increases in HbA1c were linked with declines in sperm motility and erectile function.

“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.

The trial is evaluating the efficacy of leflutrozole in improving testicular function and promoting spermatogenesis.

The TOBY test works by analyzing the molecular signatures of volatile organic compounds in urine.

The study also found racial differences in the time to proceeding with surgical therapy.

Oral sulopenem was approved by the FDA in October 2024 for the management of uUTIs.

The approach was associated with a 30% decrease in PSMA uptake by the salivary glands without compromising the treatment’s efficacy.

"Estimate how much you will need to spend each year during various stages of retirement," advises Ronald J. Paprocki, JD, CFP, CHBC.